Imaging in the Diagnosis of Parkinson's Disease and Essential Tremor

NCT ID: NCT01446939

Last Updated: 2012-10-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Parkinson´s disease (PD) diagnosis is based upon clinical examination. Although imaging has helped doctors to identify many diseases, it still does not add too much information for the diagnosis of Parkinson´s disease. The investigators are going to perform a large sample study including PD patients, essential tremor and healthy volunteers in order to evaluate if MRI can help in the diagnosis. Our hypothesis is that fractional anisotropy (FA) in the caudal portion of substantia nigra is decreased in PD patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The diagnosis of Parkinson's disease (PD) is based on a set of clinical assessments that do not provide great accuracy. Although magnetic resonance imaging (MRI) and transcranial sonography (TCS) have provided important advances in the diagnosis of a number of neurological diseases, few biomarkers of PD have been described in order to support its clinical diagnosis.

Recently, one single study showed that high field MRI using diffusion tensor imaging (DTI) was able discriminate PD from healthy volunteers. This study had a small sample size (14 patients and 14 controls) and did not include the main differential diagnosis of PD.

The main objective of this study is to confirm previous findings, with a larger sample size, describe possible changes of DTI parameters in patients with essential tremor (one of the main differential diagnosis of PD), and compare DTI MRI with TCS. Our primary outcome will be the fractional anisotropy (FA) in the caudal portion of substantia nigra. As a consequence, new algorithm to discriminate PD, essential tremor and healthy volunteers will be proposed. This has a pivotal importance in order to provide support to clinical diagnosis of PD and increase its accuracy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease Essential Tremor

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

MRI Parkinson's disease Essential tremor Ultrasonography Diagnosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson's disease

Patients with primary Parkinson's disease

No interventions assigned to this group

Essential tremor

Patients with essential tremor

No interventions assigned to this group

Healthy volunteers

Healthy volunteers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parkinson´s disease patients according to UK Parkinson´s Disease Brain Bank Criteria
* Essential Tremor Patients according to Movement Disorder´s diagnosis consensus criteria.
* Healthy Volunteers: paired with PD patients by age and gender.

Exclusion Criteria

* Contraindication to MRI
* Claustrophobia.
* Serious structural brain anomalies.
* Condition or situation in which, in the opinion of the investigator put the patient at significant risk, which can confound the results, or substantially interfere with the individual's participation in the study.
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Sao Paulo

OTHER

Sponsor Role collaborator

Hospital Israelita Albert Einstein

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ellison Fernando Cardoso

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Edson Amaro Junior, MD,PhD

Role: STUDY_CHAIR

Hospital Israelita Albert Einstein

Claudia C Leite, MD, PhD

Role: STUDY_CHAIR

Faculdade de Medicina da Universidade de São Paulo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculdade de Medicina da Universidade de São Paulo

São Paulo, São Paulo, Brazil

Site Status RECRUITING

Hospital Israelita Albert Einstein

São Paulo, São Paulo, Brazil

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ellison F Cardoso, MD, PhD

Role: CONTACT

Phone: 551121512487

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Claudia C Leite, MD,PhD

Role: primary

Ellison F Cardoso, MD, PhD

Role: backup

Ellison F Cardoso, MD, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009 Apr 21;72(16):1378-84. doi: 10.1212/01.wnl.0000340982.01727.6e. Epub 2009 Jan 7.

Reference Type BACKGROUND
PMID: 19129507 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAPPESQ8197

Identifier Type: OTHER

Identifier Source: secondary_id

IIEP1436-11

Identifier Type: -

Identifier Source: org_study_id